TB-500

TB-500 is a synthetic fragment of thymosin beta-4, used off-label for acute injury repair and inflammation reduction — no approved indication exists, so every human application is compounded and unapproved. Clinician sources converge on 2–2.5 mg subQ, with cycle lengths of 4–12 weeks; frequency guidance splits between daily and weekly dosing, and the weekly interpretation likely reflects typical practice more accurately than the daily figures. The honest caveat: the formal trial program carries a 36% withdrawal rate, and the exploratory indications circulating in the biohacking community are mostly trials without posted results — the evidence base is thinner than its reputation implies.

TB-500

Research Evidence

Evidence shape

TB-500's evidence is moderate — eleven registered trials span dry eye disease, ulcer healing, and cardiovascular conditions, but nearly every indication has a single trial behind it, and dry eye disease appears under multiple variant registration names that likely overlap. Four blinded trials have posted results from three independent sponsors, with the strongest work reaching Phase 3. A 36% withdrawal rate across registered trials and just one linked publication are the substantive limits: the signal is real but no indication has been tested at the scale that would settle clinical questions.

Depthhow much
11 registered trials
5 completed · 4 with posted results · 2 recruiting / active · combined n=225
Breadthhow many areas
12 indications mapped
7 thin / exploratory · 1 animal-only · 11 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
4 blinded with results · 3 distinct sponsors · 36% withdrawal rate · AE rows aggregated from 3 trials · 1 linked publication on registered trials
Breadth and depth35 rows captured
Human
direct clinical signal
11
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
Natty Peptides
UK
2400 mg
$40.03
$0.013/mg
2
Nextgenpeps
US
10 mg
$0.72
$0.072/mg
3
Peptide Giants
US
100 mg
$74.99
$0.75/mg
4
High Purity Peptides
HK
100 mg
$130.00
$1.3/mg
5
Peptide Titans
US
100 mg
$209.99
$2.1/mg
6
Global Peptides
UK
10 mg
$24.95
$2.5/mg

price offers can be sorted by column

1-6 of 129

Dosing & Protocol

How TB-500 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 5
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

5 completed trials identified; trial dosing not reliably extracted from registry data.

5 sources
Clinician practice
Doctor & published-protocol guidance · n = 4
Typical dose
2.5 mg2 mg – 2.5 mg
2 mg
2.5 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 2 mg–2.5 mg daily subQ (4 sources).

4 sources
Anecdotal
Community-reported real-world use · n = 9
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports highlight TB-500's use for injury repair (57.1% positive out of 7 reports) and inflammation/pain reduction (100% positive out of 2 reports). No specific dose hints were consistently reported.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for TB-500, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.